-transparent.png){kind=logo}
A 32 bp deletion in the CCR5 gene designated CCR5 delta 32 has been identified recently as the cellular basis for resistance to human immunodeficiency virus type 1 (HIV-1) in some individuals which remained non-infected despite a repeated exposure to this virus. The prevalence of this deletion was examined by polymerase chain reaction (PCR) on 51 HIV-1-infected and 385 non-infected individuals from all parts of Slovenia. 84.4% of the the HIV-1-infected and 83.2% of the non-infected individuals were homozygous for wild type CCR5, and 19.6% and 16.3%, respectively, were heterozygous. No homozygous mutant genotype was observed among the HIV-1-infected patients. Of the non-infected individuals, 2 women (0.5%) were found to harbour the CCR5 delta 32/CCR5 delta 32 genotype only, which is, to the best of our knowledge, the lowest prevalence of this particular genotype found among Caucasians to date.
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
January 2000,
AIDS research and human retroviruses,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
March 2001,
Immunology letters,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
February 2003,
Journal of acquired immune deficiency syndromes (1999),
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
November 1996,
Nature medicine,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
August 1999,
AIDS (London, England),
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
May 1998,
Journal of medical virology,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
January 2009,
HIV clinical trials,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
September 1998,
Journal of immunology (Baltimore, Md. : 1950),
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
July 2015,
AIDS research and human retroviruses,
M Poljak, and
J Tomazic, and
K Seme, and
M Maticic, and
L Vidmar
September 2008,
PloS one,
